- Home
- ADTX
ADTX
Aditxt Inc.
as 11-26-2025 3:17pm EST
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | RICHMOND |
| Market Cap: | 1.1M | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | 200.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2426.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.40 - $11017.45 | Next Earning Date: | 11-18-2025 |
| Revenue: | $5,945 | Revenue Growth: | -97.20% |
| Revenue Growth (this year): | 15768.94% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Aditxt Inc. (ADTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pankovcin Corinne | ADTX | Chief M&A Officer | Nov 25 '25 | Sell | $3.20 | 1 | $3.20 | 0 |
Latest Aditxt Inc. News
ADTX Breaking Stock News: Dive into ADTX Ticker-Specific Updates for Smart Investing
PR Newswire
a month ago
Evofem Announces Voting Results from Special Meeting of Stockholders
PR Newswire
3 months ago
Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms
PR Newswire
3 months ago
Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting
Business Wire
5 months ago
Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET
Business Wire
6 months ago
Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors
Business Wire
6 months ago
Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6
Business Wire
6 months ago
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics
GlobeNewswire
6 months ago
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
Compare ADTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADTX Aditxt Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.